Balkees Abderrahman is Postdoctoral Fellow, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, 1500 Holcombe Blvd. Unit #1354, Houston, TX 77030, United States.
- [email protected]
By using Oncotype DX test technology, researchers behind the TAILORx trial have proven that invasive and often harmful chemotherapy needn’t be the only option for women with breast cancer.
Less is more: shorter trastuzumab treatment for HER2+ breast cancer is effective, cheaper and yields better adherence than standard therapySubscription
Around 15–20% of breast cancers show amplification (increased number of gene copies) or overexpression (increased production of protein) of the human epidermal growth factor receptor 2 (HER2). These patients have highly proliferative tumours and decreased expression of oestrogen and progesterone receptors, alongside positive axillary lymph nodes (to which cancer has spread). These patients are at high risk of cancer recurrence and death. Trastuzumab (Herceptin®
On 31 October 2017, at the American Society for Reproductive Medicine in San Antonio, Patel and colleagues presented the first study to correlate chemotherapy-treated women with reduced fertility of their offspring
Breast cancer prevention trumps cureSubscription
Chemoprevention in British women is inadequateSubscription
Recent blog posts
Balkees Abderrahman highlights the problem of medication non-adherence in the treatment and prevention of breast cancer.